Generate Biomedicines, Inc.
NASDAQ:GENB · NASDAQ Global Market
+$0.13 today
Vol 2.60M · Avg 0.55M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
33.0%
avg 36.5%
ROIC
-89.4%
avg -66.7%
ROA
-61.5%
avg -47.5%
Analysis
ROE is currently the strongest return metric at 33.0% versus its period average of 36.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael T. Nally | CEO & Director | $1.08M | — | 50 | — | — |
Jason E. Silvers | President & CFO | $772,902.00 | — | 54 | — | — |
Gevorg Grigoryan | Co-Founder & CTO | $738,015.00 | — | 45 | — | — |
Laurie Lee | Chief Medical Officer of Immunology & Inflammation | — | — | 59 | — | — |
Beth Grous | Chief People Officer | — | — | 58 | — | — |
Molly Gibson | Co-Founder | — | — | — | — | — |
Noubar Afeyan | Co-founder & Independent Chair of the Board | — | — | 63 | — | — |
Dinesh de Alwis | Senior VP & Head of Clinical Drug Development | — | — | — | — | — |
Aarif Khakoo | Chief Scientific Officer | — | — | 55 | — | — |
Daria Hazuda | Senior Vice President of Discovery Strategy | — | — | — | — | — |
Sahm Nasseri | Senior Vice President of Business Development & Strategy | — | — | 41 | — | — |
Sean W. Martin | Secretary, Chief Legal Officer & General Counsel | — | — | 63 | — | — |
Kimberly White | Chief Corporate Affairs Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +38.6% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +38.6% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
No competitor data available.
Who manages GENB?
Generate Biomedicines, Inc. (GENB) lists 13 active executives. The top listed executive is Laurie Lee, Chief Medical Officer of Immunology & Inflammation.
Explore More
Continue the stock analysis
Jump to another research area for this company.